KR960007568A - 트리사이클릭 피라졸 유도체 - Google Patents

트리사이클릭 피라졸 유도체 Download PDF

Info

Publication number
KR960007568A
KR960007568A KR1019950024636A KR19950024636A KR960007568A KR 960007568 A KR960007568 A KR 960007568A KR 1019950024636 A KR1019950024636 A KR 1019950024636A KR 19950024636 A KR19950024636 A KR 19950024636A KR 960007568 A KR960007568 A KR 960007568A
Authority
KR
South Korea
Prior art keywords
methyl
pyrazol
dihydro
methoxy
indeno
Prior art date
Application number
KR1019950024636A
Other languages
English (en)
Other versions
KR100385384B1 (ko
Inventor
비흐만 위르겐
Original Assignee
프리돌린 클라우스너, 롤란트 보러
에프. 호프만-라 로슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리돌린 클라우스너, 롤란트 보러, 에프. 호프만-라 로슈 에이지 filed Critical 프리돌린 클라우스너, 롤란트 보러
Publication of KR960007568A publication Critical patent/KR960007568A/ko
Application granted granted Critical
Publication of KR100385384B1 publication Critical patent/KR100385384B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

본 발명은 일반식(I)로 트리사이클릭 피라졸 유도체 및 또한 약제학적으로 허용되는 이의 염에 관한 것이다.
상기식에서, R1내지 R4는 각각 수소, 하이드록시, 할로겐, 저급 알킬, 저급알콕시 또는 페닐이고, R5는 수소 또는 저급알킬이고, R6은 수소, 저급알킬 또는 저급 알콕시이고, X는 -(CR7R8)n-또는 -CH=CH-이고, R7및 R8은 수소 또는 저급 알킬이며, n은 1 또는 2이다.
이들 화합물 및 염은 특히 우울증, 이극성 질환, 불안상태, 수면 및 성적 장애, 정신병, 정신분열증, 편두통 및 두통 또는 상이한 종류의 통증과 관련이 기타의 상태, 개인적인 질환 또는 비만성 강박 질환, 사회 공포증 또는 공황 상태, 정신적 기관 장애, 아동 정신 질환, 공격증, 노인성 기억 질환 및 행동 질환, 중독, 비만, 병적 기아 등과 같은 중추신경 질환, 종양, 발작, 신경 퇴화성 질환 등에 의한 신경계의 손상, 고혈압, 혈전증, 발작 등과 같은 심혈관 질환 및 위장관 운동성 기능 부전과 같은 위장 질환을 치료 또는 예방하기 위한 약제학적으로 활성인 물질로서 사용하기에 적합하다.

Description

트리사이클릭 피라졸 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 일반식(I)의 화합물 및 약제학적으로 허용되는 이들의 염.
    상기식에서, R1내지 R4는 각각 수소, 하이드록시, 할로겐, 저급 알킬, 저급알콕시 또는 페닐이고, R5는 수소 또는 저급알킬이고, R6은 수소, 저급알킬 또는 저급 알콕시이고, X는 -(CR7R8)n-또는 -CH=CH-이고, R7및 R8은 수소 또는 저급 알킬이며, n은 1 또는 2이다.
  2. 제1항에 있어서, R5가 메틸인 화합물.
  3. 제1항 또는 제2항에 있어사, R2가 메틸 또는 메톡시이고 X가 -CH2- 또는 -C(CH3)2-이며 R1, R3, R4및 R6이 수소인 화합물.
  4. (RS)-2-(7-메톡시-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  5. (S)-2-(7-메톡시-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  6. (S)-2-(4,4,7-트리메틸-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  7. (S)-2-(7-메톡시-4,4-디메틸-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  8. (RS)-2-(7-메톡시-4,4-디메틸-1,4-디하이드로-인덴올[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  9. (RS)-2-(7-에톡시-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  10. (RS)-2-(7-메톡시-1,4-디하이드로-인데노[2,1-c]피라졸-1-일)-1-메틸-에틸아민 푸마레이트(1:1).
  11. (RS)-2-(8-메톡시-1-벤즈[g]인다졸-1-일)-메틸-에틸아민 푸마레이트(1:0.5).
  12. 일반식(Ⅱ)의 화합물.
    상기식에서, R1 내지 R6 및 X는 제1항에 정의한 바와 같고, R9는 아지도 그룹, 하이드록시 그룹 또는 보호된 아미노 그룹이다.
  13. 우울증, 이극성 질환, 불안상태, 수면 및 성적 장애, 정신병, 정신분열증, 편두통 및 두통 또는 상이한 종류의 통증과 관련이 기타의 상태, 개인적인 질환 또는 비만성 강박 질환, 사회 공포증 또는 공황 상태, 정신적 기관 장애, 아동 정신 질환, 공격증, 노인성 기억 질환 및 행동 질환, 중독, 비만, 병적 기아 등과 같은 중추신경 질환, 종양, 발작, 신경 퇴화성 질환 등에 의한 신경계의 손상, 고혈압, 혈전증, 발작 등과 같은 심혈관 질환 및 위장관 운동성 기능 부전과 같은 위장 질환을 치료 또는 예방하기 위한, 제1항 내지 제11항 중의 어느 한 항에 따르는 화합물과 약제학적으로 불활성인 담체 물질을 포함하는 약제학적 조성물.
  14. 일반식(Ⅱa)의 화합물을 일반식(I)의 상응하는 아미노 화합물로 전환시킴을 포함하는, 제1항 내지 제11항 중의 어느 한 항에 따르는 화합물 및 약제학적으로 허용되는 이들의 염의 제조방법.
    상기식에서, R1내지 R6및 X는 제1항에서 정의한 바와 같고, R91은 아미노 그룹으로 전환될 수 있는 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950024636A 1994-08-12 1995-08-10 트리사이클릭피라졸유도체,이의제조방법및이를포함하는약제학적조성물 KR100385384B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH02490/94-0 1994-08-12
CH249094 1994-08-12

Publications (2)

Publication Number Publication Date
KR960007568A true KR960007568A (ko) 1996-03-22
KR100385384B1 KR100385384B1 (ko) 2003-09-19

Family

ID=4234975

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950024636A KR100385384B1 (ko) 1994-08-12 1995-08-10 트리사이클릭피라졸유도체,이의제조방법및이를포함하는약제학적조성물

Country Status (31)

Country Link
US (1) US5561150A (ko)
EP (1) EP0700905B1 (ko)
JP (1) JP2755560B2 (ko)
KR (1) KR100385384B1 (ko)
CN (1) CN1056607C (ko)
AT (1) ATE207905T1 (ko)
AU (1) AU691310B2 (ko)
BR (1) BR9503630A (ko)
CA (1) CA2153937C (ko)
CO (1) CO4410331A1 (ko)
CZ (1) CZ289027B6 (ko)
DE (1) DE59509777D1 (ko)
DK (1) DK0700905T3 (ko)
ES (1) ES2164730T3 (ko)
FI (1) FI113264B (ko)
HK (1) HK1012342A1 (ko)
HU (1) HUT72066A (ko)
IL (1) IL114849A (ko)
MA (1) MA23643A1 (ko)
MY (1) MY133619A (ko)
NO (1) NO305026B1 (ko)
NZ (1) NZ272731A (ko)
PE (1) PE34096A1 (ko)
PH (1) PH31424A (ko)
PL (1) PL182480B1 (ko)
PT (1) PT700905E (ko)
RU (1) RU2152388C1 (ko)
TR (1) TR199500977A2 (ko)
TW (1) TW403738B (ko)
UY (1) UY24016A1 (ko)
ZA (1) ZA956553B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
GB9819019D0 (en) * 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9820767D0 (en) * 1998-09-23 1998-11-18 Cerebrus Ltd Chemical compounds VIII
GB9918965D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxi
GB9918962D0 (en) * 1999-08-11 1999-10-13 Cerebrus Ltd Chemical compounds xxii
US6291504B1 (en) * 1999-10-20 2001-09-18 Dupont Pharmaceuticals Company Acylsemicarbazides and their uses
US20040048844A1 (en) * 1999-10-20 2004-03-11 Bristol-Myers Squibb Pharma Company Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
DE60117247D1 (de) * 2000-03-31 2006-04-20 Purdue Research Foundation West Lafayette Phosphoramidat-prodrugs
WO2004098807A1 (en) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Method of making steel couplers for joining concrete reinforcing bars
CA2432122A1 (en) 2000-12-20 2002-08-01 Bristol-Myers Squibb Pharma Company Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands
RU2273641C2 (ru) * 2001-06-01 2006-04-10 Алькон, Инк. Пираноиндазолы, фармацевтическая композиция на их основе и их использование при лечении глаукомы
EP1392658A4 (en) * 2001-06-01 2004-10-13 Alcon Inc NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE IN THE TREATMENT OF GLAUCOMES
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
TW593302B (en) * 2001-12-20 2004-06-21 Alcon Inc Novel benzodifuranimidazoline and benzofuranimidazoline derivatives and their use for the treatment of glaucoma
AU2002367323A1 (en) * 2001-12-28 2003-07-24 Bayer Pharmaceuticals Corporation Benzothieno (3,2-
WO2003057673A1 (en) * 2001-12-28 2003-07-17 Bayer Pharmaceuticals Corporation 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
US20050119489A1 (en) * 2001-12-28 2005-06-02 Ladouceur Gaetan H. 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor
BR0314419A (pt) * 2002-08-30 2005-07-19 Alcon Inc Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
WO2004054572A2 (en) * 2002-12-13 2004-07-01 Alcon, Inc. Novel benzopyran analogs and their use for the treatment of glaucoma
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
US7129257B1 (en) * 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
AR046890A1 (es) * 2003-12-15 2005-12-28 Alcon Inc [1,4] oxazino [2,3-g] indazoles sustituidos para el tratamiento del glaucoma.
US7425572B2 (en) * 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
WO2007149728A2 (en) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US392430A (en) * 1888-11-06 Tubular lantern
GB1228792A (ko) * 1967-07-20 1971-04-21
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments

Also Published As

Publication number Publication date
EP0700905B1 (de) 2001-10-31
US5561150A (en) 1996-10-01
PL182480B1 (pl) 2002-01-31
JP2755560B2 (ja) 1998-05-20
FI953827A (fi) 1996-02-13
ATE207905T1 (de) 2001-11-15
DE59509777D1 (de) 2001-12-06
AU691310B2 (en) 1998-05-14
CN1056607C (zh) 2000-09-20
HK1012342A1 (en) 1999-07-30
ES2164730T3 (es) 2002-03-01
PH31424A (en) 1998-10-29
NZ272731A (en) 1996-09-25
CA2153937A1 (en) 1996-02-13
JPH0859623A (ja) 1996-03-05
CA2153937C (en) 2007-04-10
PL309974A1 (en) 1996-02-19
CO4410331A1 (es) 1997-01-09
IL114849A0 (en) 1995-12-08
ZA956553B (en) 1996-02-12
IL114849A (en) 1999-11-30
CZ289027B6 (cs) 2001-10-17
NO305026B1 (no) 1999-03-22
CZ9502013A3 (en) 1996-03-13
RU2152388C1 (ru) 2000-07-10
AU2838295A (en) 1996-02-22
TR199500977A2 (tr) 1996-06-21
UY24016A1 (es) 2000-12-29
NO953162L (no) 1996-02-13
TW403738B (en) 2000-09-01
PT700905E (pt) 2002-04-29
MY133619A (en) 2007-11-30
DK0700905T3 (da) 2002-02-18
FI113264B (fi) 2004-03-31
CN1131666A (zh) 1996-09-25
FI953827A0 (fi) 1995-08-11
HUT72066A (en) 1996-03-28
PE34096A1 (es) 1996-10-04
KR100385384B1 (ko) 2003-09-19
EP0700905A1 (de) 1996-03-13
BR9503630A (pt) 1996-05-28
NO953162D0 (no) 1995-08-11
MA23643A1 (fr) 1996-04-01

Similar Documents

Publication Publication Date Title
KR960007568A (ko) 트리사이클릭 피라졸 유도체
KR950011407A (ko) 트리사이클릭 1-아미노에틸피롤 유도체
RU95113149A (ru) Трициклические производные пиразола
NO20013001L (no) 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)kinoksalin-5(6H)on- derivater som er 5HT2C-agonister
CA2420996A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
MX9205242A (es) Compuestos heterociclicos que contienen nitrogeno triciclico fusionado.
HUP0303148A2 (hu) CB1 antagonista hatású 4,5-dihidro-1H-pirazol-származékok és e vegyületeket tartalmazó gyógyászati készítmények és eljárások az előállításukra
PT98393A (pt) Processo para a preparacao de derivados de quinuclidina
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
JP2003507366A5 (ko)
TR199800041T1 (xx) Heterosiklokarboksamid t�revleri ve tedavi i�in kullan�mlar�.
NO954542D0 (no) 1-Arylcykloalkylsulfider, -sulfoksyder og sulfoner for behandling av depresjon, angst og Parkinson's sykdom
KR950701623A (ko) 치환된 헥사하이드로벤조페난트리딘
ATE85334T1 (de) Bisphenylalkylpiperazin-derivate, verfahren zur herstellung und arzneimittelzubereitung.
CA2483345A1 (en) Imidazolinylmethyl aralkylsulfonamides
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
AU539177B2 (en) Amino alkoxy pyrazoles
CA2380074A1 (en) Novel amide derivatives
TH21370A (th) อนุพันธ์ไตรไซคลิกพิราโซล
ES2181387T3 (es) Derivados de azetidinocarboxamida para el tratamiento de trastornos del sistema nervioso central.
KR850001153A (ko) 카르복실산아미드 화합물 및 그 유도체의 제조방법
TH13527B (th) อนุพันธ์ไตรไซคลิกพิราโซล
CA2162706A1 (en) 1-arylcycloalkyl sulphides, sulphoxides and sulphones for the treatment of depression, anxiety and parkinson's disease
TH19066A (th) วิธีสำหรับยับยั้งการเพิ่มจำนวนเซลล์กล้ามเนื้อเรียบและภาวะการตีบของหลอดเลือด
RU93058393A (ru) Производные этаноламина, проявляющие симпатомиметическую и антиполлакиуриальную активность, способ их получения, фармацевтическая композиция, способ лечения

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080407

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee